Certolizumab pegol.
Publication
, Journal Article
Goel, N; Stephens, S
Published in: MAbs
2010
Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
MAbs
DOI
EISSN
1942-0870
Publication Date
2010
Volume
2
Issue
2
Start / End Page
137 / 147
Location
United States
Related Subject Headings
- United States
- Tumor Necrosis Factor-alpha
- Polyethylene Glycols
- Marketing
- Immunotherapy
- Immunology
- Immunoglobulin Fab Fragments
- Humans
- European Union
- Drug Approval
Citation
APA
Chicago
ICMJE
MLA
NLM
Goel, N., & Stephens, S. (2010). Certolizumab pegol. MAbs, 2(2), 137–147. https://doi.org/10.4161/mabs.2.2.11271
Goel, Niti, and Sue Stephens. “Certolizumab pegol.” MAbs 2, no. 2 (2010): 137–47. https://doi.org/10.4161/mabs.2.2.11271.
Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137–47.
Goel, Niti, and Sue Stephens. “Certolizumab pegol.” MAbs, vol. 2, no. 2, 2010, pp. 137–47. Pubmed, doi:10.4161/mabs.2.2.11271.
Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137–147.
Published In
MAbs
DOI
EISSN
1942-0870
Publication Date
2010
Volume
2
Issue
2
Start / End Page
137 / 147
Location
United States
Related Subject Headings
- United States
- Tumor Necrosis Factor-alpha
- Polyethylene Glycols
- Marketing
- Immunotherapy
- Immunology
- Immunoglobulin Fab Fragments
- Humans
- European Union
- Drug Approval